OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
AstraZeneca’s experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American Society of Clinical Oncology (ASCO) meeting. In the trial, patients switched to camizestrant after early signs of resistance detected through a blood-based liquid biopsy showed a 56% improvement in progression-free survival compared to standard therapy.
This marks the first time liquid biopsy has been used to guide treatment decisions before visible tumor growth. Dr. Eleonora Teplinsky of Valley-Mount Sinai said the early switch approach allows oncologists to “stay ahead of the curve,” potentially changing how breast cancer is treated.
The phase 3 study enrolled 3,256 women with advanced HR-positive, HER2-negative breast cancer. After at least six months of aromatase inhibitors and CDK4/6 inhibitors—like Kisqali (Novartis), Ibrance (Pfizer), or Verzenio (Eli Lilly)—315 patients with ESR1 mutations were identified and randomized. Patients receiving camizestrant plus a CDK4/6 inhibitor saw a median of 16 months without disease progression, versus 9.2 months on standard therapy with placebo.
No new safety issues were reported, and dropout rates remained low. Camizestrant is a selective estrogen receptor degrader (SERD), designed to block estrogen signaling in cancer cells—an alternative when standard hormone therapies lose effectiveness.
In a separate trial, AstraZeneca’s immunotherapy Imfinzi (durvalumab), combined with FLOT chemotherapy, reduced the risk of disease recurrence or death by 29% in early-stage gastric and esophageal cancer patients. The findings support earlier intervention with immunotherapy and are expected to influence global treatment practices.
AstraZeneca CEO Pascal Soriot emphasized the importance of proactive monitoring, calling it the future of cancer care. Both studies were simultaneously published in the New England Journal of Medicine.
